WO2008089339A3 - Oligosaccharide conjugates for cellular targeting - Google Patents

Oligosaccharide conjugates for cellular targeting Download PDF

Info

Publication number
WO2008089339A3
WO2008089339A3 PCT/US2008/051327 US2008051327W WO2008089339A3 WO 2008089339 A3 WO2008089339 A3 WO 2008089339A3 US 2008051327 W US2008051327 W US 2008051327W WO 2008089339 A3 WO2008089339 A3 WO 2008089339A3
Authority
WO
WIPO (PCT)
Prior art keywords
mannose
oligosaccharide conjugates
phosphate
proteins
cellular targeting
Prior art date
Application number
PCT/US2008/051327
Other languages
French (fr)
Other versions
WO2008089339A2 (en
Inventor
Karen L Lee
Robert J Mattaliano
James E Stefano
Original Assignee
Genzyme Corp
Karen L Lee
Robert J Mattaliano
James E Stefano
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp, Karen L Lee, Robert J Mattaliano, James E Stefano filed Critical Genzyme Corp
Publication of WO2008089339A2 publication Critical patent/WO2008089339A2/en
Publication of WO2008089339A3 publication Critical patent/WO2008089339A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

This disclosure relates to conjugation of therapeutic proteins (e.g., lysosomal enzymes) with oligosaccharides comprising mannose-6-phosphate. Conjugation of proteins with oligosaccharides comprising mannose-6-phosphate results in protein-oligosaccharide conjugates that are targeted to the lysosome by mannose-6-phosphate receptors. The proteins of the invention may be used in enzyme replacement therapy of, e.g., lysosomal storage disorders.
PCT/US2008/051327 2007-01-18 2008-01-17 Oligosaccharide conjugates for cellular targeting WO2008089339A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88545707P 2007-01-18 2007-01-18
US60/885,457 2007-01-18

Publications (2)

Publication Number Publication Date
WO2008089339A2 WO2008089339A2 (en) 2008-07-24
WO2008089339A3 true WO2008089339A3 (en) 2008-09-18

Family

ID=39434207

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/051327 WO2008089339A2 (en) 2007-01-18 2008-01-17 Oligosaccharide conjugates for cellular targeting

Country Status (1)

Country Link
WO (1) WO2008089339A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9493498B2 (en) 2008-12-16 2016-11-15 Genzyme Corporation Oligosaccharide-protein conjugates

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7723296B2 (en) 2001-01-18 2010-05-25 Genzyme Corporation Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof
LT2457920T (en) 2007-01-18 2018-02-12 Genzyme Corporation Oligosaccharides comprising an aminooxy group and conjugates thereof
CA2766614C (en) * 2009-07-03 2018-06-19 Inserm (Institut National De La Sante Et De La Recherche Medicale) Compounds targeting the cation-independent mannose 6-phosphate receptor
WO2012101671A1 (en) * 2011-01-25 2012-08-02 Jcr Pharmaceuticals Co., Ltd. Method for production of human recombinant iduronate 2-sulfatase
TW201925236A (en) 2017-10-02 2019-07-01 美商戴納立製藥公司 Fusion proteins comprising enzyme replacement therapy enzymes
CN113301925A (en) * 2018-12-19 2021-08-24 小利兰·斯坦福大学理事会 Bifunctional molecules for lysosomal targeting and related compositions and methods

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020137125A1 (en) * 2001-01-18 2002-09-26 Yunxiang Zhu Methods for introducing mannose 6-phosphate and other oligosacharides onto glycoroteins and its application thereof
WO2003031464A2 (en) * 2001-10-10 2003-04-17 Neose Technologies, Inc. Remodeling and glycoconjugation of peptides
US20050048047A1 (en) * 2003-08-29 2005-03-03 Kakkis Emil D. Delivery of therapeutic compounds to the brain and other tissues
WO2005094874A1 (en) * 2004-04-01 2005-10-13 Zymenex A/S Medical use of alpha-mannosidase

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020137125A1 (en) * 2001-01-18 2002-09-26 Yunxiang Zhu Methods for introducing mannose 6-phosphate and other oligosacharides onto glycoroteins and its application thereof
WO2003031464A2 (en) * 2001-10-10 2003-04-17 Neose Technologies, Inc. Remodeling and glycoconjugation of peptides
US20050048047A1 (en) * 2003-08-29 2005-03-03 Kakkis Emil D. Delivery of therapeutic compounds to the brain and other tissues
WO2005094874A1 (en) * 2004-04-01 2005-10-13 Zymenex A/S Medical use of alpha-mannosidase

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9493498B2 (en) 2008-12-16 2016-11-15 Genzyme Corporation Oligosaccharide-protein conjugates

Also Published As

Publication number Publication date
WO2008089339A2 (en) 2008-07-24

Similar Documents

Publication Publication Date Title
WO2008089339A3 (en) Oligosaccharide conjugates for cellular targeting
MX2019009191A (en) Targeted therapeutic lysosomal enzyme fusion proteins and uses thereof.
AU2011270668A8 (en) CNS delivery of therapeutic agents
MX349749B (en) Intraventricular enzyme delivery for lysosomal storage diseases.
WO2008063511A3 (en) Methods for treating pompe disease
WO2006042146A3 (en) Multifunctional nanoparticles conjugates and their use
WO2007105027A8 (en) Anticancer drugs conjugated to antibody via an enzyme cleavable linker
HK1121530A1 (en) Assays for detection of antibodies to lysosomal enzymes
EP3608330A3 (en) Synthetic intermediates for preparing oligosaccharide-protein conjugates
WO2008089403A3 (en) Oligosaccharides comprising an aminooxy group and conjugates thereof
WO2012166653A3 (en) Methods for coupling targeting peptides onto recombinant lysosomal enzymes
EP4253395A3 (en) Processes for the preparation of carbohydrate conjugated rna agents
IL207446A0 (en) Acid alpha-glucosidase and fragments thereof
WO2010148253A3 (en) Formulations for lysosomal enzymes
WO2004084950A3 (en) Cell targeting methods and compositions
MX2010004674A (en) Alpha-amylase variants with altered properties.
WO2008028117A3 (en) Glp-2 mimetibodies, polypeptides, compositions, methods and uses
MX2013000321A (en) Cns delivery of therapeutic agents.
WO2006063055A3 (en) Enzyme conjugates for use as detoxifying agents
WO2008112525A8 (en) Treatment of lysosomal storage diseases
IN2012MN02262A (en)
WO2012012718A3 (en) Manufacture of active highly phosphorylated human n-acetylgalactosamine-6-sulfatase and uses thereof
WO2008103920A3 (en) Targeted protein cages
WO2012138694A3 (en) Compositions comprising saccharide binding moieties and methods for targeted therapy
WO2006122123A3 (en) Methods of alleviating disorders and their associated pain

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08727847

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08727847

Country of ref document: EP

Kind code of ref document: A2